Blink Health LLC, a provider of consumer price discounts for prescription drugs, said it has terminated its relationship with Express Scripts Holding Co., a pharmacy-benefit manager that helped arrange the new price break for Lilly’s insulin.
NYS Entity Status
NYS Filing Date
MAY 02, 2014
NYS DOS ID#
NYS Entity Type
DOMESTIC LIMITED LIABILITY COMPANY
2014 - 330 MAIN ST. HOLDINGS, LLC
AROUND THE WEB
- Blink Health Ends Pact With Express Scripts for Lilly Insulin Price Discounts
Tuesday Jun 13, 2017
- Holding Back TV News? Not For Sweeps Or Main Newscasts
Tuesday May 16, 2017
Media viewers shouldn't be teasing into waiting for those big TV news stories that come around four times a year, during sweeps. Trouble is, traditional local TV programming is still where TVstations' bread is buttered -- where they make the most bang for their buck with advertisers.
- Belgium Holds Four for Questioning in Terror Probe
Thursday Jun 22, 2017
Belgian federal prosecutors said four people were taken into custody for questioning as part of a probe into the attempted terrorist attack at Brussels’ main train station earlier this week.
- Greg David on NY: Why developing in Midtown remains a Herculean task
Monday Jun 19, 2017
To view the full story, click the title link.
- Pulse@MassChallenge Spurs Deals in Digital Health Lab’s 1st Session
By Jeff Engel - Wednesday Jun 14, 2017
The refrain among digital health startups is it can be difficult and time-consuming to convince hospitals and other healthcare organizations to try out their products, let alone buy them. Pulse@MassChallenge, a new Boston “lab” dedicated to supporting digital health ventures, matches startups with partner organizations—think hospitals, insurers, larger tech companies, nonprofits, and government entities—to collaborate […]
- “It’s Shame On Us If We Blow It”: Highlights From NY Seizes the Momentum
By Ben Fidler - Wednesday Jun 7, 2017
Mike Foley, a drug industry veteran and director of the Tri-Institutional Therapeutics Discovery Institute, has a pointed message for the New York life sciences industry: Don’t waste the moment. Changing the course of New York biotech has been a saga that dates back to the 1990s, and as Xconomy has detailed, progress has been made […]
- New Approvals Show FDA Is Adapting to Precision Medicine
By Frank Vinluan - Tuesday May 30, 2017
The randomized controlled trial has long been held up as the gold standard for testing new drugs. But the nation’s top drug evaluator, Janet Woodcock, believes they aren’t necessary for all new experimental treatments. Randomized trials are long, expensive to run, and ultimately produce limited answers, she said at a medical conference last week. The […]
- Getting an Edge in the Long Afghan Struggle
Friday Jun 23, 2017
Trump’s early approach holds promise if backed with a sustained, and sustainable, commitment.